Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Freya Meds vs GoodRx

Freya Meds
Graded #365

Lower grade

vs+10.999999999999993
GoodRx
Graded #116

Higher grade

The verdict

GoodRx takes it — 69.6/100 to 58.6/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +37
43
80
Dose & formulationGoodRx +6
64
70
Clinical oversightFreya Meds +2
71
69
Labs & monitoringFreya Meds +9
60
51
FulfillmentGoodRx +19
62
81
Contract termsEven
55
55
Freya Meds · left barGoodRx · right bar

The numbers

MetricFreya MedsGoodRx
WeighScore58.6/10069.6/100
GradeCC
Scorecard rank#365#116
Semaglutide$297/mo (compounded)Not disclosed
Tirzepatide$390/mo (compounded)$299/mo (brand Zepbound)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Freya Meds

Graded #365 · C

Strengths

  • GLP-1 specialist — not a multi-category telehealth
  • Price includes unlimited doctor consultations, monthly group calls, and a dietitian consultation
  • Both semaglutide and tirzepatide available
  • Multi-month discount on quarterly billing
  • Claims 450,000+ enrolled

Where it loses points

  • No visible LegitScript or PCAB accreditation
  • Above-average pricing ($250–$390/mo)
  • Compounded only — no brand-name options
  • Now serves 49 U.S. states (one state excluded; specific exclusion not named)
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard